LianBio (LIAN) Social Stream
LIANBIO (LIAN) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering LIANBIO.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-24 | 3 | $27 | $27 | $27 | $4.17 | 547.48% |
| 2021-12-09 | 3 | $27 | $24 | $25.5 | $4.17 | 511.51% |
| 2021-12-10 | 3 | $28 | $24 | $26.333 | $4.17 | 531.49% |
| 2022-01-05 | 3 | $27 | $20 | $23.666 | $4.17 | 467.53% |
| 2022-03-31 | 3 | $27 | $16 | $22.333 | $4.17 | 435.56% |
| 2022-05-12 | 3 | $27 | $13 | $20 | $4.17 | 379.62% |
| 2022-09-17 | 3 | $27 | $13 | $18.666 | $4.17 | 347.63% |
| 2022-10-14 | 3 | $20 | $13 | $16 | $4.17 | 283.69% |
| 2022-10-31 | 3 | $16 | $13 | $14.666 | $4.17 | 251.7% |
| 2022-12-19 | 3 | $15 | $8 | $12 | $4.17 | 187.77% |
| 2022-12-20 | 3 | $15 | $7 | $10 | $4.17 | 139.81% |
| 2023-03-28 | 3 | $15 | $7 | $9.666 | $4.17 | 131.8% |
| 2023-08-18 | 2 | $7 | $6 | $6.5 | $4.17 | 55.88% |
| 2023-10-26 | 3 | $9 | $6 | $7.333 | $4.17 | 75.85% |
| 2023-11-17 | 2 | $7 | $5 | $6 | $4.17 | 43.88% |
| 2023-12-22 | 2 | $5 | $4 | $4.5 | $4.17 | 7.91% |
| NA | 1 | $NA | $NA | $NA | $4.17 | NA% |
The Trend in the Analyst Price Target
LIAN's average price target has moved down $22.5 over the prior 25 months.
LIAN reports an average of 293.28% for its upside potential over the past 47 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-02-08 | 3 | 15 | 7 | 9.666 | 2.28 | 323.95% |
| 2023-03-27 | 3 | 15 | 7 | 9.666 | 1.67 | 478.8% |
| 2023-03-28 | 3 | 15 | 7 | 9.666 | 1.65 | 485.82% |
| 2023-08-18 | 3 | 15 | 6 | 9.333 | 1.85 | 404.49% |
| 2023-11-17 | 2 | 7 | 5 | 6.000 | 4.15 | 44.58% |
LIAN Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2 | 1 | 0 | 1 | 0 | 0 | 2 |
The Trend in the Broker Recommendations
LIAN's average broker recommendation rating worsened by 0.67 over the prior 25 months.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for LIAN as an investment opportunity.
- LIANBIO's number of analysts covering the stock is higher than 119.19% of all US stocks.
- In the context of all US stocks, LIANBIO's upside potential (average analyst target price relative to current price) is greater than 1508.73% of them.
- In the context of Pharmaceutical Products stocks, LIANBIO's variance in analysts' estimates is lower than -423.18% of them.
- LIAN has a higher average analyst price target than 474.03% of Healthcare stocks.
Stocks similar to LIANBIO in the Pharmaceutical Products industry regarding analyst recommendations and price targets are ANTX, BLTE, and PEPG.
View All Top Stocks by Price Target
Make investment decisions regarding LIAN using the data that counts. Try POWR Ratings for free.